Pharma Start
Pharma Start is recorded as a service provider in 26 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 26 trials · Latest update first
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients
Sponsor Satellos Bioscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus
Sponsor Cabaletta Bio Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
Sponsor Dyne Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1
Sponsor Spur Therapeutics Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy
Sponsor Cabaletta Bio Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Subjects with Peripheral Manifestations of Gaucher Disease
Sponsor Prevail Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Sponsor Dyne Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT)
Sponsor Ipsen Pharma
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705.
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
AN OPEN-LABEL PHASE 2 STUDY TO EVALUATE PT2977 FOR THE TREATMENT OF VONHIPPEL-LINDAU DISEASE-ASSOCIATED RENAL CELL CARCINOMA
Sponsor Peloton Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD)
Sponsor Ipsen Pharma
- Start (EU)
- Latest update
- Estimated end
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (The ACTION Study)
Sponsor Chimerix Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double‑blind, Placebo‑controlled, Dose‑finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Sponsor Alexion Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Pharma Start?
The 2026-10-09 snapshot links Pharma Start to 26 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Home Health, Home Health Services, among 22 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pharma Start?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Immunology, Neurology, Metabolic Disorders. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pharma Start conducted?
The linked trials record locations in 21 countries, including Spain, Italy, Germany, France, Belgium. These are trial locations, not confirmed office locations or countries where Pharma Start delivered services.
What can this page tell me about Pharma Start's trial experience?
Browse 26 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Pharma Start. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Pharma Start LLC